Detalhe da pesquisa
1.
Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
Pediatr Transplant
; 26(6): e14292, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35466492
2.
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(11): 1566-1575, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562043
3.
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
Lancet Oncol
; 19(8): 1061-1071, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29941280
4.
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
J Clin Oncol
; 42(10): 1135-1145, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190578
5.
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Neuro Oncol
; 24(6): 997-1007, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34850167
6.
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
J Clin Oncol
; 39(27): 2979-2990, 2021 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34343032
7.
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
Eur J Cancer
; 100: 27-34, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29936064
8.
Older adolescents and young adults with cancer: a different subset of patients?
Clin Transl Oncol
; 8(6): 383-4, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16790388
9.
Prognostic factors in neuroblastoma: the need for evidence-based decisions in prospective studies.
Clin Transl Oncol
; 7(1): 1-2, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15890148
10.
Rhabdomyosarcoma: present and future perspectives in diagnosis and treatment.
Clin Transl Oncol
; 7(1): 35-41, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15890156
11.
Prognostic factors in desmoid tumours: an example of translational oncology.
Clin Transl Oncol
; 13(3): 139-40, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21421456
12.
Oral manifestations of Langerhans cell histiocytosis. Case study of a two-year-old boy.
Med Oral
; 8(1): 19-25, 2003.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-12556719
13.
Teràpia molecular en el càncer pediàtric: noves perspectives en la utilització danticossos monoclonals / No disponible
Pediatr. catalan
; 68(3): 104-105, mayo-jun. 2008.
Artigo
em Espanhol
| IBECS (Espanha) | ID: ibc-76748
14.
Older adolescents and young adults with cancer: a different subset of patients?
Clin. transl. oncol. (Print)
; 8(6): 383-384, jun. 2006.
Artigo
em En
| IBECS (Espanha) | ID: ibc-047688
15.
Prognostic factors in neuroblastoma: the need for evidence-based decisions in prospective studies
Clin. transl. oncol. (Print)
; 7(1): 1-2, ene.-feb. 2005.
Artigo
em En
| IBECS (Espanha) | ID: ibc-038813
16.
Rhabdomyosarcoma: present and future perspectives in diagnosis and treatment
Clin. transl. oncol. (Print)
; 7(1): 35-41, ene.-feb. 2005. tab
Artigo
em En
| IBECS (Espanha) | ID: ibc-038821
17.
Manifestaciones orales de la Histiocitosis de células de Langerhans. A propósito del caso de un niño de dos años / Oral manifestations of Langerhans cell Histiocytosis. Case study of a two-year-old boy
Med. oral
; 8(1): 19-25, ene. 2003.
Artigo
em Es
| IBECS (Espanha) | ID: ibc-17150